Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (91-100 of 509) with videos related to

Pageof 51
Sort By:
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 28, 2010
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetesKristine J Hare, Tina Vilsbøll, Jens J Holst, et al.
Medical Hypotheses|October 5, 2011
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?Annesofie Faurschou, Claus Zachariae, Lone Skov, et al.
Diabetes, Obesity & Metabolism|May 28, 2011
Glucagon antagonism as a potential therapeutic target in type 2 diabetesJ I Bagger, F K Knop, J J Holst, et al.
Diabetes, Obesity & Metabolism|October 18, 2022
Semaglutide for the treatment of overweight and obesity: A reviewNatasha Chidekel Bergmann, Melanie J Davies, Ildiko Lingvay, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 27, 2011
Electroretinography in healthy subjects in relation to systemic glucocorticoid intakePer Kappelgaard, Katrine B Hansen, Tina Vilsbøll, et al.
Endocrine|April 24, 2025
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatmentMiriam Longo, Maria Ida Maiorino, Dario Giugliano, et al.
Expert Opinion on Drug Discovery|August 15, 2014
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitusMikkel Christensen, Patrick Miossec, Bjarne Due Larsen, et al.
Basic & Clinical Pharmacology & Toxicology|August 21, 2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor TreatmentHeidi Storgaard, Jonatan I Bagger, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism|March 3, 2010
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?Meena Asmar, Michael Bache, Filip K Knop, et al.
Pageof 51

Showing results (91-100 of 509) with videos related to

Sort By:
Pageof 51
Current Opinion in Molecular Therapeutics|December 15, 2010
Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetesEspen Jimenez-Solem, Mette H Rasmussen, Mikkel Christensen, et al.
American Journal of Physiology. Endocrinology and Metabolism|January 28, 2010
Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetesKristine J Hare, Tina Vilsbøll, Jens J Holst, et al.
Medical Hypotheses|October 5, 2011
Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?Annesofie Faurschou, Claus Zachariae, Lone Skov, et al.
Diabetes, Obesity & Metabolism|May 28, 2011
Glucagon antagonism as a potential therapeutic target in type 2 diabetesJ I Bagger, F K Knop, J J Holst, et al.
Diabetes, Obesity & Metabolism|October 18, 2022
Semaglutide for the treatment of overweight and obesity: A reviewNatasha Chidekel Bergmann, Melanie J Davies, Ildiko Lingvay, et al.
Documenta Ophthalmologica. Advances in Ophthalmology|December 27, 2011
Electroretinography in healthy subjects in relation to systemic glucocorticoid intakePer Kappelgaard, Katrine B Hansen, Tina Vilsbøll, et al.
Endocrine|April 24, 2025
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatmentMiriam Longo, Maria Ida Maiorino, Dario Giugliano, et al.
Expert Opinion on Drug Discovery|August 15, 2014
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitusMikkel Christensen, Patrick Miossec, Bjarne Due Larsen, et al.
Basic & Clinical Pharmacology & Toxicology|August 21, 2015
Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor TreatmentHeidi Storgaard, Jonatan I Bagger, Filip K Knop, et al.
The Journal of Clinical Endocrinology and Metabolism|March 3, 2010
Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?Meena Asmar, Michael Bache, Filip K Knop, et al.
Pageof 51